Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sunder Biomedical Tech CoROCO:4115 +0.38%52 PB Ratio is 0.62 as of Jul. 14, 2026, which is 36% below its 10-year median of 0.97. GuruFocus rates ROCO:4115 with a GF Score™ of 52/100 and a GF Value™ of NT$10.70 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 788 Medical Devices & Instruments companies, Sunder Biomedical Tech Co ranks better than 89.72% on this metric.
The historical rank and industry rank for Sunder Biomedical Tech Co's PB Ratio or its related term are showing as below:
ROCO:4115'
s PB Ratio Range Over the Past 10 Years
Min: 0.55 Med: 0.97 Max: 2.05
Current: 0.62
During the past 8 years, Sunder Biomedical Tech Co's highest PB Ratio was 2.05. The lowest was 0.55. And the median was 0.97.
ROCO:4115's PB Ratio is ranked better than 89.72% of 788
companies
in the Medical Devices & Instruments industry
Industry Median: 2.05
vs ROCO:4115: 0.62
During the past 12 months, Sunder Biomedical Tech Co's average Book Value Per Share Growth Rate was -2.50% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -1.40% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -0.50% per year.
During the past 8 years, the highest 3-Year average Book Value Per Share Growth Rate of Sunder Biomedical Tech Co was 5.50% per year. The lowest was -1.40% per year. And the median was -0.90% per year.
Back to Basics: PB Ratio
Sunder Biomedical Tech Co (ROCO:4115) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Sunder Biomedical Tech Co PB Ratio Related Terms
Sunder Biomedical Tech Co PB Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, Sunder Biomedical Tech Co's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sunder Biomedical Tech Co PB Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Sunder Biomedical Tech Co's PB Ratio distribution charts can be found below:
* The bar in red indicates where Sunder Biomedical Tech Co's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Sunder Biomedical Tech Co (ROCO:4115) has a PB Ratio of 0.62 as of Jul. 14, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Sunder Biomedical Tech Co and its competitors. This is 36% below median its historical median of 0.97. Over the past decade, Sunder Biomedical Tech Co's PB Ratio has ranged from 0.55 to 2.05. According to the industry distribution chart, Sunder Biomedical Tech Co ranks #81 out of 788 companies in the Medical Devices & Instruments industry, placing it in the top 10.3%.
Is Sunder Biomedical Tech Co's PB Ratio too high?
Sunder Biomedical Tech Co's current PB Ratio of 0.62 is 36% below median its 10-year median of 0.97. Over the past 10 years, this metric has ranged from a low of 0.55 to a high of 2.05. The Medical Devices & Instruments industry median PB Ratio is 2.05. Sunder Biomedical Tech Co's value of 0.62 is 69.8% below this industry median. Based on the distribution chart, Sunder Biomedical Tech Co ranks #81 out of 788 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Sunder Biomedical Tech Co has a GF Score™ of 52/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sunder Biomedical Tech Co's PB Ratio compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Sunder Biomedical Tech Co ranks #81 out of 788 companies for PB Ratio. This places Sunder Biomedical Tech Co in the top 10% of its industry — outperforming the majority of peers. The industry median PB Ratio is 2.05. Sunder Biomedical Tech Co's value of 0.62 is 69.8% below this benchmark. Historically, Sunder Biomedical Tech Co's own PB Ratio has ranged from 0.55 to 2.05 over the past decade. While the company's 10-year median is 0.97 vs. the industry median of 2.05, Sunder Biomedical Tech Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Medical Devices & Instruments company?
The median PB Ratio among Medical Devices & Instruments companies is 2.05, based on 788 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sunder Biomedical Tech Co's current PB Ratio of 0.62 is 69.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Sunder Biomedical Tech Co and its competitors. For the Medical Devices & Instruments industry, the median PB Ratio is 2.05 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sunder Biomedical Tech Co's current PB Ratio is 0.62, which is 36% below median its own 10-year median of 0.97. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sunder Biomedical Tech Co stock overvalued right now?
Based on GuruFocus' analysis, Sunder Biomedical Tech Co (ROCO:4115) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$10.70, compared to a current price of NT$7.86 — trading 26.5% below its estimated fair value. The current PB Ratio is 0.62, which is 36% below median its 10-year median of 0.97 and 69.8% below the Medical Devices & Instruments industry median of 2.05. Sunder Biomedical Tech Co's overall GF Score™ is 52/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Sunder Biomedical Tech Co (ROCO:4115), the current PB Ratio is 0.62 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sunder Biomedical Tech Co (ROCO:4115) Overvalued in 2026?
Based on GuruFocus' analysis, Sunder Biomedical Tech Co stock appears to be undervalued.
The current stock price of NT$7.86 is trading 26.5% below its estimated GF Value™ of NT$10.70.
GuruFocus considers Sunder Biomedical Tech Co to be Modestly Undervalued.
Key valuation signals for ROCO:4115:
PB Ratio: 0.62 (36% below median its 10-year median of 0.97)
GF Value™: NT$10.70 vs. price of NT$7.86 (26.5% below fair value)
Industry Position: 69.8% below the Medical Devices & Instruments median (#81 of 788)
No single metric tells the full story. See the ROCO:4115 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sunder Biomedical Tech Co Ltd is engaged in providing medical devices. Its products include Protective Goggles; Meltblown Nonwoven Fabric/Mask; Suction Irrigation Set; Smoke Filter; Endo Bag; Blood Line Set for Hemodialysis and others.
52GF Score
Get the complete analysis for ROCO:4115
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4115 has been successfully added to your 
